Literature DB >> 11594503

Comparative investigation of proliferation markers and their prognostic relevance in human meningiomas.

S H Torp1, C F Lindboe, U S Granli, T M Moen, T Nordtømme.   

Abstract

OBJECTIVE: In human meningiomas, histology alone does not always predict the clinical outcome. Proliferative activity has therefore, become a potential tool in the histopathological grading of these tumors. The aim of this study was to investigate different Ki67 antibodies on meningiomas, to compare their proliferation indices (PI) and with other proliferation markers, such as S-phase fraction and mitotic activity, and to see whether these factors correlate with histological tumor grade.
MATERIAL AND METHODS: The study included 43 meningiomas graded according to the criteria of WHO and Jääskeläinen et al. [1985, 1986]. Paraffin sections were used for immunohistochemical detection of Ki67 antigen and flow-cytometric determination of S-phase fraction.
RESULTS: The PIs displayed an overall increase with increasing histological grade, however, the range of values for benign, atypical and anaplastic meningiomas were wide, resulting in considerable overlap between the groups. There were for the most significant correlations between the different proliferation markers.
CONCLUSIONS: Ki67-equivalent antibodies and S phase fraction have no advantage over counting mitoses to assess the proliferative activity in meningiomas. Thus, mitotic activity justifies its role in meningioma grading.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11594503

Source DB:  PubMed          Journal:  Clin Neuropathol        ISSN: 0722-5091            Impact factor:   1.368


  10 in total

1.  Immunohistochemical characterization of brain-invasive meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Magnus B Arnli; Kathrin Torseth; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2014-09-15

2.  The histopathological spectrum of human meningiomas.

Authors:  Thomas Backer-Grøndahl; Bjørnar H Moen; Sverre H Torp
Journal:  Int J Clin Exp Pathol       Date:  2012-03-25

3.  MCM7 expression is a promising predictor of recurrence in patients surgically resected for meningiomas.

Authors:  Theo L Winther; Sverre H Torp
Journal:  J Neurooncol       Date:  2016-11-21       Impact factor: 4.130

Review 4.  Pathological classification and molecular genetics of meningiomas.

Authors:  Christian Mawrin; Arie Perry
Journal:  J Neurooncol       Date:  2010-09-01       Impact factor: 4.130

5.  Cyclin D1 immunoreactivity in meningiomas.

Authors:  Sanja Milenković; Tatjana Marinkovic; Milan B Jovanovic; Slavisa Djuricic; Ivana I Berisavac; Iva Berisavac
Journal:  Cell Mol Neurobiol       Date:  2008-04-01       Impact factor: 5.046

6.  Long Term Surgical Outcome and Prognostic Factors of Atypical and Malignant Meningiomas.

Authors:  Yu-Chi Wang; Chi-Cheng Chuang; Kuo-Chen Wei; Cheng-Nen Chang; Shih-Tseng Lee; Chieh-Tsai Wu; Yung-Hsin Hsu; Tzu-Kan Lin; Peng-Wei Hsu; Yin-Cheng Huang; Chen-Kan Tseng; Chun-Chieh Wang; Yao-Liang Chen; Pin-Yuan Chen
Journal:  Sci Rep       Date:  2016-10-20       Impact factor: 4.379

7.  The anti-apoptotic protein survivin can improve the prognostication of meningioma patients.

Authors:  Theo L Winther; Sverre H Torp
Journal:  PLoS One       Date:  2017-09-27       Impact factor: 3.240

8.  DNA topoisomerase IIα and mitosin expression predict meningioma recurrence better than histopathological grade and MIB-1 after initial surgery.

Authors:  Theo L Winther; Sverre H Torp
Journal:  PLoS One       Date:  2017-03-16       Impact factor: 3.240

9.  Prognostic Factors of Atypical Meningioma: Overall Survival Rate and Progression Free Survival Rate.

Authors:  Jae Ho Lee; Oh Lyong Kim; Young Beom Seo; Jun Hyuk Choi
Journal:  J Korean Neurosurg Soc       Date:  2017-10-25

10.  Immunohistochemical expression of h-telomerase reverse transcriptase in canine and feline meningiomas.

Authors:  Luciana Mandrioli; Serena Panarese; Alessandro Cesari; Maria Teresa Mandara; Paolo Stefano Marcato; Giuliano Bettini
Journal:  J Vet Sci       Date:  2007-06       Impact factor: 1.672

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.